{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T05:09:53Z","timestamp":1745471393963},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>The primary percutaneous coronary intervention (PPCI) is the preferred reperfusion strategy for ST-segment elevation myocardial infarction (STEMI). The pharmacoinvasive strategy (PIs) is a reasonable alternative when prompt PPCI is not possible, especially in resource-limited regions. We aimed to compare PPCI versus PIs outcomes in Peru.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a retrospective cohort study based on the second Peruvian Registry of STEMI (PERSTEMI II). We compared the characteristics, in-hospital outcomes and 30-day mortality of patients undergoing PPCI during the first 12\u00a0h and those receiving a PIs. A propensity score-matched analysis was conducted to compare the effects of each treatment strategy on clinical outcomes.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>PIs patients were younger than PPCI patients, had a shorter first medical contact time, first medical contact to reperfusion time, and total ischemic time until reperfusion. Successful PCI was more frequent in the PIs group (84.4% vs. 71.1%, <jats:italic>p<\/jats:italic>\u2009=\u20090.035). There were no differences between PIs and PPCI in terms of total in-hospital mortality (5.2% vs. 6.6%, <jats:italic>p<\/jats:italic>\u2009=\u20090.703), cardiovascular mortality (4.2% vs. 5.3%, <jats:italic>p<\/jats:italic>\u2009=\u20090.735), cardiogenic shock (8.3% vs. 13.2%, <jats:italic>p<\/jats:italic>\u2009=\u20090.326), heart failure (19.8% vs. 30.3%, <jats:italic>p<\/jats:italic>\u2009=\u20090.112), or major bleeding (0% vs. 2.6%, <jats:italic>p<\/jats:italic>\u2009=\u20090.194). In the propensity score-matched analysis, the rates of cardiovascular mortality, postinfarction heart failure and successful reperfusion were similar.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In this real-world study, no differences were found in the in-hospital outcomes between patients with STEMI who received PIs or PPCI.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12872-022-02730-6","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T12:03:02Z","timestamp":1656504182000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Outcomes in ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention or pharmacoinvasive strategy in a Latin American country"],"prefix":"10.1186","volume":"22","author":[{"given":"Manuel","family":"Chac\u00f3n-Diaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piero","family":"Custodio-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paol","family":"Rojas De la Cuba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Germ\u00e1n","family":"Y\u00e1bar-Galindo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e9","family":"Rodr\u00edguez-Olivares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Miranda-No\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Marcos","family":"L\u00f3pez-Rojas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akram","family":"Hern\u00e1ndez-V\u00e1squez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,29]]},"reference":[{"issue":"4","key":"2730_CR1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.cjco.2020.11.012","volume":"3","author":"D Araiza-Garaygordobil","year":"2020","unstructured":"Araiza-Garaygordobil D, Gopar-Nieto R, Cabello-L\u00f3pez A, Martinez-Amezcua P, Eid-Lidt G, Baeza-Herrera LA, et al. Pharmacoinvasive strategy vs primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: results from a study in Mexico city. CJC Open. 2020;3(4):409\u201318. https:\/\/doi.org\/10.1016\/j.cjco.2020.11.012.","journal-title":"CJC Open"},{"issue":"12","key":"2730_CR2","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.rec.2017.11.010","volume":"70","author":"B Ib\u00e1nez","year":"2017","unstructured":"Ib\u00e1nez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Rev Esp Cardiol (Engl Ed). 2017;70(12):1082. https:\/\/doi.org\/10.1016\/j.rec.2017.11.010 (English, Spanish).","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"10","key":"2730_CR3","doi-asserted-by":"publisher","first-page":"e008059","DOI":"10.1161\/CIRCINTERVENTIONS.119.008059","volume":"12","author":"KR Bainey","year":"2019","unstructured":"Bainey KR, Armstrong PW, Zheng Y, Brass N, Tyrrell BD, Leung R, et al. Pharmacoinvasive strategy versus primary percutaneous coronary intervention in ST-elevation myocardial infarction in clinical practice: insights from the Vital Heart Response Registry. Circ Cardiovasc Interv. 2019;12(10):e008059. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.119.008059.","journal-title":"Circ Cardiovasc Interv"},{"issue":"15","key":"2730_CR4","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1056\/NEJMoa1301092","volume":"368","author":"PW Armstrong","year":"2013","unstructured":"Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2013;368(15):1379\u201387. https:\/\/doi.org\/10.1056\/NEJMoa1301092.","journal-title":"N Engl J Med"},{"issue":"9","key":"2730_CR5","doi-asserted-by":"publisher","first-page":"e003508","DOI":"10.1161\/CIRCINTERVENTIONS.115.003508","volume":"9","author":"DS Sim","year":"2016","unstructured":"Sim DS, Jeong MH, Ahn Y, Kim YJ, Chae SC, Hong TJ, et al. Pharmacoinvasive strategy versus primary percutaneous coronary intervention in patients with ST-segment-elevation myocardial infarction: a propensity score-matched analysis. Circ Cardiovasc Interv. 2016;9(9):e003508. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.115.003508.","journal-title":"Circ Cardiovasc Interv"},{"issue":"2","key":"2730_CR6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.47487\/apcyccv.v2i2.132","volume":"2","author":"M Chac\u00f3n-Diaz","year":"2021","unstructured":"Chac\u00f3n-Diaz M, Rodr\u00edguez Olivares R, Miranda-No\u00e9 D, Custodio-S\u00e1nchez P, Montesinos C\u00e1rdenas A, Yabar Galindo G, et al. Treatment of acute myocardial infarction in Peru and its relationship with in-hospital adverse events: results from the Second Peruvian Registry of ST-segment Elevation Myocardial Infarction (PERSTEMI-II). Arch Peru Cardiol Cir Cardiovasc. 2021;2(2):113\u201322. https:\/\/doi.org\/10.47487\/apcyccv.v2i2.132.","journal-title":"Arch Peru Cardiol Cir Cardiovasc"},{"issue":"5","key":"2730_CR7","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.acmx.2017.11.009","volume":"88","author":"M Chac\u00f3n-Diaz","year":"2018","unstructured":"Chac\u00f3n-Diaz M, Vega A, Ar\u00e1oz O, Rios P, Baltodano R, Villanueva F, et al. Epidemiological characteristics of ST-segment elevation myocardial infarction in Peru: Results of the PEruvian Registry of ST-segment Elevation Myocardial Infarction (PERSTEMI). Arch Cardiol Mex. 2018;88(5):403\u201312. https:\/\/doi.org\/10.1016\/j.acmx.2017.11.009.","journal-title":"Arch Cardiol Mex"},{"issue":"3","key":"2730_CR8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.acmx.2016.04.007","volume":"86","author":"C Martinez-Sanchez","year":"2016","unstructured":"Martinez-Sanchez C, Borrayo G, Carrillo J, Juarez U, Quintanilla J, Jerjes-Sanchez C. Clinical management and hospital outcomes of acute coronary syndrome patients in Mexico: the Third National Registry of Acute Coronary Syndromes (RENASICA III). Arch Cardiol Mex. 2016;86(3):221\u201332. https:\/\/doi.org\/10.1016\/j.acmx.2016.04.007.","journal-title":"Arch Cardiol Mex"},{"key":"2730_CR9","doi-asserted-by":"publisher","first-page":"548","DOI":"10.7775\/rac.es.v84.i6.9508","volume":"84","author":"J Gagliardi","year":"2016","unstructured":"Gagliardi J, Charask A, Perna E, D\u00b4Imperio H, Bono J, Castillo Costa Y, et al. National survey of ST-segment elevation acute myocardial infarction in Argentina (ARGEN-IAM- T). Rev Argent Cardiol. 2016;84:548\u201357. https:\/\/doi.org\/10.7775\/rac.es.v84.i6.9508.","journal-title":"Rev Argent Cardiol"},{"issue":"1","key":"2730_CR10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.17843\/rpmesp.2020.371.4527","volume":"37","author":"PR Navarro","year":"2020","unstructured":"Navarro PR, Pariona M, Urquiaga Calder\u00f3n JA, M\u00e9ndez Silva FJ. Clinical and epidemiological characteristics of acute myocardial infarction in a referral Peruvian hospital. Rev Peru Med Exp Salud Publica. 2020;37(1):74\u201380. https:\/\/doi.org\/10.17843\/rpmesp.2020.371.4527.","journal-title":"Rev Peru Med Exp Salud Publica"},{"key":"2730_CR11","unstructured":"Reyes M, Ruiz E. National Registry of Acute Myocardial Infarction II (RENIMA II). Revista Peruana de Cardiolog\u00eda Enero\u2013Abril 2013, pp. 60\u201371. http:\/\/repebis.upch.edu.pe\/articulos\/rpc\/v39n1\/a2.pdf."},{"issue":"26","key":"2730_CR12","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1056\/NEJMoa0808276","volume":"360","author":"WJ Cantor","year":"2009","unstructured":"Cantor WJ, Fitchett D, Borgundvaag B, Ducas J, Heffernan M, Cohen EA, et al. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med. 2009;360(26):2705\u201318. https:\/\/doi.org\/10.1056\/NEJMoa0808276.","journal-title":"N Engl J Med"},{"issue":"24","key":"2730_CR13","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1053\/euhj.2001.2686","volume":"22","author":"F Van de Werf","year":"2001","unstructured":"Van de Werf F, Barron HV, Armstrong PW, Granger CB, Berioli S, Barbash G, et al. Assessment of the safety and efficacy of a new thrombolytic. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA. Eur Heart J. 2001;22(24):2253\u201361. https:\/\/doi.org\/10.1053\/euhj.2001.2686.","journal-title":"Eur Heart J"},{"issue":"3","key":"2730_CR14","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1161\/CIRCULATIONAHA.107.762765","volume":"118","author":"N Danchin","year":"2008","unstructured":"Danchin N, Coste P, Ferri\u00e8res J, Steg PG, Cottin Y, Blanchard D, et al. Comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary percutaneous coronary intervention for ST-segment-elevation acute myocardial infarction: data from the French registry on acute ST-elevation myocardial infarction (FAST-MI). Circulation. 2008;118(3):268\u201376. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.762765.","journal-title":"Circulation"},{"issue":"16","key":"2730_CR15","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1161\/CIRCULATIONAHA.113.005874","volume":"129","author":"N Danchin","year":"2014","unstructured":"Danchin N, Puymirat E, Steg PG, Goldstein P, Schiele F, Belle L, et al. Five-year survival in patients with ST-segment-elevation myocardial infarction according to modalities of reperfusion therapy: the French registry on acute ST-elevation and non-ST-elevation myocardial infarction (FAST-MI) 2005 cohort. Circulation. 2014;129(16):1629\u201336. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.005874.","journal-title":"Circulation"},{"issue":"9","key":"2730_CR16","doi-asserted-by":"publisher","first-page":"e003508","DOI":"10.1161\/CIRCINTERVENTIONS.115.003508","volume":"9","author":"DS Sim","year":"2016","unstructured":"Sim DS, Jeong MH, Ahn Y, Kim YJ, Chae SC, Hong TJ, Korea Acute Myocardial Infarction Registry (KAMIR) Investigators, et al. Pharmacoinvasive strategy versus primary percutaneous coronary intervention in patients with ST-segment-elevation myocardial infarction: a propensity score-matched analysis. Circ Cardiovasc Interv. 2016;9(9):e003508. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.115.003508.","journal-title":"Circ Cardiovasc Interv"},{"issue":"6","key":"2730_CR17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.jcin.2011.02.012","volume":"4","author":"AE Denktas","year":"2011","unstructured":"Denktas AE, Anderson HV, McCarthy J, Smalling RW. Total ischemic time: the correct focus of attention for optimal ST-segment elevation myocardial infarction care. JACC Cardiovasc Interv. 2011;4(6):599\u2013604. https:\/\/doi.org\/10.1016\/j.jcin.2011.02.012.","journal-title":"JACC Cardiovasc Interv"},{"issue":"7","key":"2730_CR18","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jacc.2008.05.009","volume":"52","author":"G Ndrepepa","year":"2008","unstructured":"Ndrepepa G, Mehilli J, Schulz S, Iijima R, Keta D, Byrne RA, et al. Prognostic significance of epicardial blood flow before and after percutaneous coronary intervention in patients with acute coronary syndromes. J Am Coll Cardiol. 2008;52(7):512\u20137. https:\/\/doi.org\/10.1016\/j.jacc.2008.05.009.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2730_CR19","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.amjcard.2014.06.011","volume":"114","author":"RC Welsh","year":"2014","unstructured":"Welsh RC, Van de Werf F, Westerhout CM, Goldstein P, Gershlick AH, Wilcox RG, et al. Outcomes of a pharmacoinvasive strategy for successful versus failed fibrinolysis and primary percutaneous intervention in acute myocardial infarction (from the STrategic Reperfusion Early After Myocardial Infarction [STREAM] study). Am J Cardiol. 2014;114(6):811\u20139. https:\/\/doi.org\/10.1016\/j.amjcard.2014.06.011.","journal-title":"Am J Cardiol"},{"key":"2730_CR20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2147\/IJGM.S292901","volume":"14","author":"J Nan","year":"2021","unstructured":"Nan J, Meng S, Hu H, Jia R, Jin Z. Fibrinolysis therapy combined with deferred PCI versus primary angioplasty for STEMI patients during the COVID-19 pandemic: preliminary results from a single center. Int J Gen Med. 2021;14:201\u20139. https:\/\/doi.org\/10.2147\/IJGM.S292901.","journal-title":"Int J Gen Med"},{"issue":"4","key":"2730_CR21","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.amjcard.2018.04.057","volume":"122","author":"TJ Siddiqi","year":"2018","unstructured":"Siddiqi TJ, Usman MS, Khan MS, Sreenivasan J, Kassas I, Riaz H, et al. Meta-analysis comparing primary percutaneous coronary intervention versus pharmacoinvasive therapy in transfer patients with ST-elevation myocardial infarction. Am J Cardiol. 2018;122(4):542\u20137. https:\/\/doi.org\/10.1016\/j.amjcard.2018.04.057.","journal-title":"Am J Cardiol"},{"issue":"14","key":"2730_CR22","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1161\/CIRCULATIONAHA.114.009570","volume":"130","author":"PR Sinnaeve","year":"2014","unstructured":"Sinnaeve PR, Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Lambert Y, et al. ST-segment-elevation myocardial infarction patients randomized to a pharmaco-invasive strategy or primary percutaneous coronary intervention: Strategic Reperfusion Early After Myocardial Infarction (STREAM) 1-year mortality follow-up. Circulation. 2014;130(14):1139\u201345. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.009570.","journal-title":"Circulation"},{"issue":"1","key":"2730_CR23","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13256-017-1322-3","volume":"11","author":"S Arous","year":"2017","unstructured":"Arous S, Haboub M, El Ghali BM, Bentaoune T, Habbal R. Ischemic stroke complicating thrombolytic therapy with tenecteplase for ST elevation myocardial infarction: two case reports. J Med Case Rep. 2017;11(1):154. https:\/\/doi.org\/10.1186\/s13256-017-1322-3.","journal-title":"J Med Case Rep"},{"key":"2730_CR24","doi-asserted-by":"publisher","first-page":"100684","DOI":"10.1016\/j.ijcha.2020.100684","volume":"31","author":"A Albaeni","year":"2020","unstructured":"Albaeni A, Harris CM, Nasser H, Sifontes S, Hasan SM, Guduru S, et al. In-Hospital acute ischemic stroke following ST-elevation myocardial infarction. Int J Cardiol Heart Vasc. 2020;31:100684. https:\/\/doi.org\/10.1016\/j.ijcha.2020.100684.","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"9030","key":"2730_CR25","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(96)02514-7","volume":"348","author":"E Boersma","year":"1996","unstructured":"Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet. 1996;348(9030):771\u20135. https:\/\/doi.org\/10.1016\/S0140-6736(96)02514-7.","journal-title":"Lancet"},{"issue":"2","key":"2730_CR26","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ahj.2010.10.033","volume":"161","author":"CM Westerhout","year":"2011","unstructured":"Westerhout CM, Bonnefoy E, Welsh RC, Steg PG, Boutitie F, Armstrong PW. The influence of time from symptom onset and reperfusion strategy on 1-year survival in ST-elevation myocardial infarction: a pooled analysis of an early fibrinolytic strategy versus primary percutaneous coronary intervention from CAPTIM and WEST. Am Heart J. 2011;161(2):283\u201390. https:\/\/doi.org\/10.1016\/j.ahj.2010.10.033.","journal-title":"Am Heart J"},{"issue":"9612","key":"2730_CR27","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S0140-6736(08)60268-8","volume":"371","author":"C Di Mario","year":"2008","unstructured":"Di Mario C, Dudek D, Piscione F, Mielecki W, Savonitto S, Murena E, et al. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. Lancet. 2008;371(9612):559\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(08)60268-8.","journal-title":"Lancet"},{"issue":"5","key":"2730_CR28","first-page":"539","volume":"68","author":"Z Siudak","year":"2010","unstructured":"Siudak Z, Rakowski T, Dziewierz A, Janzon M, Birkemeyer R, Stefaniak J, et al. Early abciximab use in ST-elevation myocardial infarction treated with primary percutaneous coronary intervention improves long-term outcome. Data from EUROTRANSFER Registry. Kardiol Pol. 2010;68(5):539\u201343.","journal-title":"Kardiol Pol"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-022-02730-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-022-02730-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-022-02730-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T12:04:21Z","timestamp":1656504261000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-022-02730-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,29]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2730"],"URL":"https:\/\/doi.org\/10.1186\/s12872-022-02730-6","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,29]]},"assertion":[{"value":"31 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted after obtaining approval from the Ethics and Research Committee of the National Cardiovascular Institute, INCOR. All methods were performed in accordance with the relevant guidelines and regulations (Declaration of Helsinki). Informed consent was obtained from all subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"296"}}